{"id":91395,"date":"2026-11-17T15:52:00","date_gmt":"2026-11-17T15:52:00","guid":{"rendered":"https:\/\/english.saigonbiz.com\/vn\/?p=91395"},"modified":"2026-11-18T02:16:28","modified_gmt":"2026-11-18T02:16:28","slug":"viral-vector-manufacturing-market-to-reach-usd-12-91-billion-by-2035-as-gene-therapy-developers-weigh-scale-cost-and-capacity","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/viral-vector-manufacturing-market-to-reach-usd-12-91-billion-by-2035-as-gene-therapy-developers-weigh-scale-cost-and-capacity\/","title":{"rendered":"Viral Vector Manufacturing Market to Reach USD 12.91 Billion by 2035 as Gene Therapy Developers Weigh Scale, Cost and Capacity"},"content":{"rendered":"<p><em>Market Climbs from USD 2.21 Billion in 2026 at a 21.64% CAGR: North America Leads, Asia-Pacific Is the Fastest-Growing Region and AAV Vectors Hold the Largest Type Share<\/em><\/p>\n<p>Ottawa, Nov.  17, 2026  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vw1nzCYxgMK8R0P5s8Sli5alOitcyCH38z6xi826DJYZFutOlEZXEVJzpYr9AcOiRXj0e5a7vFoqHF2Svib3PY7uPdxd1LAJHa1s29XM2kQj61gbVWjJxsja3cxNQS-5TUbgqDkBLA4ZMB4ocpItRf9CALdkt6qoOnDtoVRjlZW6IAbuNUXw_bl7yjFBqema\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Viral vector manufacturing<\/b><\/a>, the upstream production, downstream purification and quality control of engineered, replication-deficient viruses that deliver genetic material into cells, now sits at the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0drjTPWVwcpblKb21oXjPnvgeImPSoXtViogKcqxlBzrmhkMR75w0vjV_Ra9u4CzS8OcoVYaLenz40uJX8IQ1ail2dTsoB_DBojEW7rDH1JK3HgJdVbO-xtBoYb4V4XuYjJx0cfRrVFA2JsWUXfwcN9pARAroKE51sPaXgv1UNED6tWzXO_lqwb9nBFRoHmQ\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>center of cell and gene therapy pipelines<\/b><\/a>, vaccines and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=B9z3pQdbqDxvhrhh30uDfgXT8NZb9dTYBO8MjaY_a_4ry-jOA_2JxABm_pbBLp5SdT107hxHiCROOJPM6aysWDF4RYxJmGJCKISxKNI7P6XM15hxDItNU_baJBXLi6t5XzxB60UiBPUVuIkxibC40T9Hy2y_s1Mu5F8cBhl_BkipqCdZ8vP5Wf0BosyOfx6Y\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>advanced biopharmaceuticals<\/b><\/a>. Towards Healthcare, a sister firm of Precedence Research, estimates the global market at USD 2.21 billion in 2026 and forecasts USD 12.91 billion by 2035, an absolute increase of USD 10.70 billion in nine years.<\/p>\n<p>The 2026 evidence points in two directions at once. FDA\u2019s Center for Biologics Evaluation and Research finalized CMC flexibilities for cell and gene therapy license applications on 5 May 2026, REGENXBIO is preparing a Duchenne muscular dystrophy BLA for the first quarter of 2027, and Oxford Biomedica (OXB) signed a record 17 new clients in the first half. Yet VintaBio, a Philadelphia viral vector and vaccine manufacturer, made an assignment for the benefit of creditors on 27 October 2026, and OXB lowered its 2026 revenue guidance to \u00a3180\u2013200 million as clients shifted order timing.<\/p>\n<p>For executives, the question is no longer whether demand exists. It is which vector types, sites and partners will carry commercial volume, how much capacity is worth committing, and where across North America, Europe and Asia-Pacific that capacity will earn its return.<\/p>\n<p><b>Full report:<\/b> <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=h8FqNakEpM16OLnYnahIu3jjFIIBmvr7gNOu2YWZuudBgtk6EvLMC_pSJ5q6fsFv4FPba-qk3FGiAolgRqHsz0dK63LKcSnVd9RprMdsfhagEExQKdjWsSfM2mwntOIu-m7U-y3wCFt0TC3KqYgGOcKsvxAbJMWLeYLx-oH6iVuYOVn59zeSAGZ3ycvm-ehFWFjyShNR4WEoxEngi8yvD0IJN7HYS3JqyUP60uTscxkhf-kjTmxqHq4vTADZi3gyBuaO91s0-CHBtW0BF8z_nA==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>https:\/\/www.towardshealthcare.com\/insights\/viral-vector-manufacturing-market-sizing<\/u><\/a><\/p>\n<p><b>Request a sample:<\/b> <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=h8FqNakEpM16OLnYnahIu3jjFIIBmvr7gNOu2YWZuucxZsNTDBHq5_8VPnUZ7GcvVhTjvjBnL4Y7ZRBpNV_dWPBfEMEi1894u8X28I49U0X98lornHPB5Xb2J6_IdaDLupv2aYxjD-YWsNYTbZFX3vQQzlKa-fPO2iGojujJjkM=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>https:\/\/www.towardshealthcare.com\/sample\/5631<\/u><\/a><\/p>\n<p><b>Market Size and Growth<\/b><\/p>\n<table style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; border-collapse: collapse; width:100%; border-collapse:collapse ;\">\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Market Indicator<\/b><\/td>\n<td colspan=\"2\" style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Value<\/b><\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Market size, 2025 (base year)<\/td>\n<td colspan=\"2\" style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">USD 1.82 billion<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Market size, 2026<\/td>\n<td colspan=\"2\" style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">USD 2.21 billion<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Forecast market size, 2035<\/td>\n<td colspan=\"2\" style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">USD 12.91 billion<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">CAGR, 2026\u20132035<\/td>\n<td style=\"border-top: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: top ; \">21.64<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: top ; \">%<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Absolute growth, 2026\u20132035 (calculated)<\/td>\n<td colspan=\"2\" style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">USD 10.70 billion<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Leading region<\/td>\n<td colspan=\"2\" style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">North America<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Fastest-growing region<\/td>\n<td colspan=\"2\" style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Asia-Pacific<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Leading type \/ disease<\/td>\n<td colspan=\"2\" style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Adeno-associated viral (AAV) vectors \/ Cancer<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Leading application \/ end-user<\/td>\n<td colspan=\"2\" style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Gene therapy \/ Pharmaceutical and biopharmaceutical companies<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Report code \/ last updated<\/td>\n<td colspan=\"2\" style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">5631 \/ 20 August 2026<\/td>\n<\/tr>\n<\/table>\n<p align=\"center\" style=\"text-align:center;\"><img decoding=\"async\" height=\"300.0px\" name=\"GNW_RichHtml_IMG\" src=\"https:\/\/ml.globenewswire.com\/Resource\/Download\/b15b9ea2-5b8a-4481-a1f1-0950a39c2afb\/image1.png\" width=\"601.0px\" data-dpi=\"96\" data-filename=\"image1.png\" \/><\/p>\n<p align=\"center\" style=\"text-align:center;\"><b>Figure 1: Viral vector manufacturing market snapshot, 2025\u20132035<\/b><\/p>\n<p>Growth rests on the rising prevalence of genetic disorders and cancers, larger gene therapy clinical pipelines and a steady run of regulatory approvals. On the supply side, suspension-based production, single-use systems, process automation and advanced purification are improving consistency and scalability, while pharmaceutical sponsors keep committing capital to advanced therapies.<\/p>\n<p><i>Sources: Expert Interview, Secondary Sources, Towards Healthcare Database, Towards Healthcare Analysts and Researcher<\/i><\/p>\n<p><b>Segment Intelligence: Dominant and Fastest-Growing Segments<\/b><\/p>\n<table style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; border-collapse: collapse; width:100%; border-collapse:collapse ;\">\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: top ; \"><b>Segment Group<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: top ; \"><b>Leading<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: top ; \"><b>Fastest-Growing<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: top ; \"><b>Why It Matters<\/b><\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: top ; \">Type<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: top ; \">AAV vectors (largest share, 2024)<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: top ; \">Adenoviral vectors (significant growth, 2024)<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: top ; \">AAV pipelines set the demand for specialized capacity; adenoviral vectors serve vaccines and oncology<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: top ; \">Disease<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: top ; \">Cancer<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: top ; \">Infectious diseases<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: top ; \">Oncology anchors current volume; vaccines open a second demand curve<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: top ; \">Application<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: top ; \">Gene therapy<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: top ; \">Vaccinology<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: top ; \">Gene therapy drives commercial-scale supply; vaccine platforms favor scalable processes<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: top ; \">End-user<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: top ; \">Pharmaceutical and biopharmaceutical companies<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: top ; \">Research institutes<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: top ; \">Sponsors buy scale; institutes buy clinical-grade vector for early programs<\/td>\n<\/tr>\n<\/table>\n<p align=\"center\" style=\"text-align:center;\"><img decoding=\"async\" height=\"300.0px\" name=\"GNW_RichHtml_IMG\" src=\"https:\/\/ml.globenewswire.com\/Resource\/Download\/48dc8122-02c6-4d2c-8f5a-1758e869345a\/image2.png\" width=\"601.0px\" data-dpi=\"96\" data-filename=\"image2.png\" \/><\/p>\n<p align=\"center\" style=\"text-align:center;\"><b>Figure 2: Leading and fastest-growing segments<\/b><\/p>\n<p><b>By type,<\/b> AAV vectors held the largest share in 2024 on a favorable safety profile, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=J4sgYS7duLcC2vaPY_jYpeoTbUJ-6c16c9JvZCh7GyFQ4IDKl_68M-h-ALw-ptgOk0JZsNvoBU9wiSd7jyxpefmRQ4osLM8MByyrJh8pS6gcwhN4WwAtxDpDR1AnhQ06AC0MdbISrt30Ph58CtDSWkgsx8nmZHAdE2mB6R2w_QM=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>long-term gene expression<\/b><\/a> and a growing pipeline of AAV-based therapies that has pulled specialized infrastructure into place. Adenoviral vectors also posted significant growth, backed by high transduction efficiency; in a 2024 clinical trial, the oncolytic adenovirus TILT-123 showed safety and tumor-targeting promise in advanced solid cancers.<\/p>\n<p><b>By disease,<\/b> cancer led in 2024 as CAR-T and oncolytic virus-based treatments <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=h6-bCSlDMo3HynRrFKz5GHMJ8z9go6ScJJBhz_CYJhCr7jCV-P327fn21pkz1NNiWl7ILPpmW1UPXZum45nWIXeCZ4kAKPfnYU8elnqBJqybsxatk30cs6_HL5uEKoHJRaoo9aOY9Ago-0XOPWnt2jkBVkgJnQ__Rt-42uLNksU=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>expanded alongside oncology R&amp;D<\/b><\/a>. Infectious diseases are expected to grow fastest on demand for new vaccines against HIV, malaria and tuberculosis and on better <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JW4G0rQtpqtqzqesb9HLn-UQnulKuyf_n5Mu8fMRNiwvCabjczPzEzGHn0feMazXe0uVSvoFACYg1L2Nh9_5YfhZDOscLSgCRPTQ0fquh4gZxHvrFP0tTePW1QgcsaZxhFXHgFGkadM6lq2X08w4ApGwlv2BM36w5AJmre6Ec8U=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>molecular diagnostics<\/b><\/a> and surveillance. An estimated 2 million new U.S. cancer diagnoses in 2024 keep oncology demand visible.<\/p>\n<p><b>By application,<\/b> gene therapy accounted for the highest share in 2024 as AAV advances improved delivery efficiency and approvals accelerated vector demand. Vaccinology is projected to grow fastest, helped by new platforms, more scalable production and public research support.<\/p>\n<p><b>By end-user,<\/b> pharmaceutical and biopharmaceutical companies led in 2024 by expanding in-house capacity, forming collaborations and scaling for commercial supply. Research institutes are estimated to grow fastest as public and private funding and academia-industry links lift demand for specialized tools.<\/p>\n<p><i>Sources: Expert Interview, Secondary Sources, Towards Healthcare Database, Towards Healthcare Analysts and Researcher<\/i><\/p>\n<p><b>Regional and Country Analysis<\/b><\/p>\n<table style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; border-collapse: collapse; width:100%; border-collapse:collapse ;\">\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Region<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Position<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Country Signals<\/b><\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">North America<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Leading region<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">U.S. and Canada<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Asia-Pacific<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Fastest-growing region<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">China, India, South Korea<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Europe<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Significant growth expected<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">UK, Germany<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Middle East &amp; Africa<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Growing area<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">South Africa<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Latin America<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Covered in the report<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Brazil, Mexico, Argentina<\/td>\n<\/tr>\n<\/table>\n<p><b>North America<\/b> led in 2024 on biopharmaceutical infrastructure, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0f_UMjiZBqiEvaR_ZEbJZZpbjb2WAS9ij5YVsLGltC6m4szjC-rMJwppergM9044HX4N_ajxbvgVzu2lEOcPJHZl142nVUHisYiN2h2xdP9XvEyX8T7fqPnITd973zyB1Q-bDFPEllq2DjAC0HZ-jeEjlq3IWSGv6YOv0qyg4cc2dOBkULOh_fB9hvkgbmt3har-QM6ShwIYnt-z_E6IWA==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>gene therapy investment and supportive regulation<\/b><\/a>. In the U.S., FDA\u2019s CBER set out a flexible approach to CMC for cell and gene therapies on 11 January 2026 and finalized guidance on 5 May. REGENXBIO reported USD 251.0 million in cash at 30 September 2026 and a pre-BLA meeting planned for the fourth quarter. The VintaBio asset sale, with bids due 15 December 2026, shows the other side of the cycle. In Canada, Virica Biotech and FUJIFILM Biosciences began an AAV yield collaboration on 8 April 2026 under a National Research Council program.<\/p>\n<p><b>Asia-Pacific<\/b> is expected to grow fastest on biotechnology investment, rising gene therapy demand and cost-effective manufacturing. In China, Porton Advanced received an NMPA Class C drug manufacturing license on 5 August 2026, which allows commercial contract manufacturing of cell and gene therapy products. In India, Nucelion Therapeutics, a Bharat Biotech subsidiary, agreed on 21 October 2026 to manufacture VeGen Bio\u2019s dual-target CAR-T candidate, building on Bharat Biotech\u2019s 50,000-square-foot cell and gene therapy and viral vector site at Genome Valley.<\/p>\n<p><b>Europe<\/b> benefits from Horizon Europe\u2019s EUR 11.5 billion research allocation and more than EUR 1 billion from InvestEU for biotechnology and medicine projects. In the UK, OXB reported first-half 2026 revenue of \u00a379.8 million, up 9%, and brought its Durham, North Carolina site online. In Germany, ProBioGen\u2019s Berlin facility received extended GMP authorization on 10 November 2026 covering viral vectors, viral vaccines and advanced therapy medicinal products. Merck KGaA reported Q3 2026 net sales of EUR 5.6 billion, up 5.1% organically, with Process Solutions the main growth driver.<\/p>\n<p><b>Middle East &amp; Africa<\/b> is growing on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=h6-bCSlDMo3HynRrFKz5GKYcNIWEOkcA6r27EOiIkQUAKiYVLts1kEVefc6_Mbt9q2v4npnedd2oH_oTCSaMQQfGeaNB5fScQYgOz5kk8yaaB0Y_ufxw6HekjgAmwE9OHzmF7Auxi6Cn5GYUBhgiFjWun-dYr4Dcv4K4uLZ6Avc=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>expanding biologics infrastructure<\/b><\/a> and rising chronic and infectious disease burden. The report counts 11 viral vector manufacturers across Africa, 10 of them with operational formulation, fill and finish capacity.<\/p>\n<p><b>What Is Changing in the Industry<\/b><\/p>\n<p><b>1. Regulators ease the path to licensure<\/b><\/p>\n<p>On 11 January 2026, FDA\u2019s CBER published its flexible approach to CMC for cell and gene therapies, and on 5 May 2026 it finalized guidance on CMC flexibilities for biologics license applications. Sponsors gain room on product specifications and validation approach, particularly for small patient populations. A mid-2026 draft guidance extended platform-data leveraging to genome-editing products.<\/p>\n<p><b>What it indicates:<\/b> Process immaturity is a smaller barrier to filing, but a defensible control strategy still decides outcomes, which favors partners with strong analytics and comparability experience.<\/p>\n<p><b>2. Capacity reset begins<\/b><\/p>\n<p>VintaBio, a purpose-built cGMP viral vector and vaccine manufacturer with demonstrated AAV8 production, made an assignment for the benefit of creditors on 27 October 2026. Its assignee is accepting bids for the facility, equipment and know-how until 5:00 p.m. ET on 15 December 2026.<\/p>\n<p><b>What it indicates:<\/b> Installed capacity is not the same as usable capacity. Buyers can acquire ready sites at lower cost, while sponsors should test partner balance sheets alongside technical fit.<\/p>\n<p><b>3. CDMO demand builds, but order timing is lumpy<\/b><\/p>\n<p>OXB reported H1 2026 revenue of \u00a379.8 million, up 9%, with 17 new clients, 59 active programs, a USD 730 million new-business pipeline up 30% and a revenue backlog of about \u00a3193 million. Full-year revenue guidance now stands at \u00a3180\u2013200 million, down from the \u00a3220\u2013240 million issued with 2025 results. OXB also signed a commercial supply agreement with Bristol Myers Squibb for lentiviral vectors supporting its CAR-T portfolio.<\/p>\n<p><b>What it indicates:<\/b> Late-stage and commercial programs are arriving, yet revenue follows client decisions rather than capacity, so forecasts need program-level visibility.<\/p>\n<p><b>4. Scale CDMOs consolidate their position<\/b><\/p>\n<p>Lonza reported H1 2026 sales of CHF 3.4 billion, up 16% at constant exchange rates, and on 14 October 2026 held its Capital Markets Day at the Vacaville, California biologics site it bought from Roche in 2024. It confirmed a full-year outlook of 11\u201312% CER sales growth and a CORE EBITDA margin of 33\u201334%.<\/p>\n<p><b>What it indicates:<\/b> Integrated, pure-play CDMO platforms are converting acquired capacity into margin, raising the bar for smaller providers.<\/p>\n<p><b>5. Regional manufacturing nodes widen<\/b><\/p>\n<p>Porton Advanced\u2019s NMPA license in China and Nucelion\u2019s CAR-T manufacturing agreement in India, both in the second half of 2026, add commercial-stage and cost-competitive options outside the U.S. and Europe.<\/p>\n<p><b>What it indicates:<\/b> Sponsors can dual-source across regions, which pressures pricing and lengthens the list of qualified suppliers.<\/p>\n<p><b>Key Market Drivers<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:4pt;\"><b>Genetic disorders and cancer:<\/b> Rising prevalence sustains demand for AAV and lentiviral delivery in precision therapies.<\/li>\n<li style=\"margin-bottom:4pt;\"><b>Maturing pipelines:<\/b> REGENXBIO\u2019s RGX-202 BLA is on track for the first quarter of 2027, and Novartis began U.S. sales of ITVISMA in the first quarter of 2026.<\/li>\n<li style=\"margin-bottom:4pt;\"><b>Regulatory flexibility:<\/b> FDA\u2019s January and May 2026 CMC actions reduce filing friction for cell and gene therapies.<\/li>\n<li style=\"margin-bottom:4pt;\"><b>Process innovation:<\/b> Suspension-based production, single-use systems, automation and continuous processing raise yield and consistency.<\/li>\n<li style=\"margin-bottom:4pt;\"><b>Public and private investment:<\/b> Horizon Europe, InvestEU and Canadian innovation funding support capacity and research.<\/li>\n<\/ul>\n<p><b>Major Challenges<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:4pt;\"><b>Complex production:<\/b> Strict quality standards, long approval timelines and high facility costs raise entry barriers.<\/li>\n<li style=\"margin-bottom:4pt;\"><b>Capacity mismatches:<\/b> The VintaBio assignment shows that specialized sites can fail when utilization lags.<\/li>\n<li style=\"margin-bottom:4pt;\"><b>Order-timing risk:<\/b> OXB\u2019s revised 2026 guidance reflects client ordering shifts rather than lost demand.<\/li>\n<li style=\"margin-bottom:4pt;\"><b>Skills and technology transfer:<\/b> Limited specialist talent slows scale-up and site-to-site transfer.<\/li>\n<li style=\"margin-bottom:4pt;\"><b>Safety setbacks:<\/b> REGENXBIO\u2019s RGX-121 Hunter syndrome program is under a clinical hold, which has moved its targeted BLA resubmission.<\/li>\n<\/ul>\n<p><b>Emerging Opportunities<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:4pt;\"><b>Vaccine platforms:<\/b> Vaccinology is the fastest-growing application, and ProBioGen\u2019s Berlin authorization targets sterile viral drug substance.<\/li>\n<li style=\"margin-bottom:4pt;\"><b>Yield and cost gains:<\/b> The FUJIFILM Biosciences\u2013Virica collaboration pairs HEK293 media with enhancers to lift AAV productivity.<\/li>\n<li style=\"margin-bottom:4pt;\"><b>Capacity acquisition:<\/b> Ready cGMP sites such as VintaBio\u2019s let buyers shorten timelines and reduce capital outlay.<\/li>\n<li style=\"margin-bottom:4pt;\"><b>Regional hubs:<\/b> China and India are adding commercial-grade and cost-competitive vector capacity.<\/li>\n<li style=\"margin-bottom:4pt;\"><b>Research-institute demand:<\/b> The fastest-growing end-user group needs clinical-grade vector for early programs.<\/li>\n<\/ul>\n<p><b>Company and Competitive Intelligence<\/b><\/p>\n<p>The report names Merck KGaA, Lonza, BD, FUJIFILM Biotechnologies, Brammer Bio, Cell Therapy Catapult, Waisman Biomanufacturing, GENEZEN, Yposkesi and REGENXBIO among the leading participants. The field mixes CDMOs, tool and reagent suppliers and gene therapy developers with in-house plants, so competition runs on platform breadth, vector expertise and regulatory track record.<\/p>\n<table style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; border-collapse: collapse; width:100%; border-collapse:collapse ;\">\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Company<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Role or Key Products<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Latest Reported Data<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Strategic Direction<\/b><\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Lonza<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Global CDMO; integrated biologics<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">H1 2026 sales CHF 3.4 billion, up 16% CER; FY2026 outlook 11\u201312% CER growth<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Completed pure-play CDMO shift; upgraded growth model on 14 Oct 2026<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">OXB<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Viral vector CDMO (lentiviral, AAV, adenoviral)<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">H1 2026 revenue \u00a379.8 million, up 9%; backlog about \u00a3193 million<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Durham, NC site online; ambition of about \u00a3500 million revenue by 2030<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Merck KGaA<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Process Solutions; reagents; viral vector services<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Q3 2026 net sales EUR 5.6 billion, up 5.1% organic<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Integrated viral vector offer via the USD 600 million Mirus Bio acquisition<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">FUJIFILM Biotechnologies \/ Biosciences<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">CDMO; BalanCD HEK293 media<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">AAV enhancer collaboration with Virica announced 8 Apr 2026<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Media plus enhancers to lift AAV yield and cut cost of goods<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">REGENXBIO<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">AAV developer; in-house manufacturing center<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Cash USD 251.0 million at 30 Sep 2026<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">RGX-202 BLA planned for Q1 2027; sura-vec data due Q4 2026<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">ProBioGen<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Viral vector and vaccine CDMO, Berlin<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Extended GMP authorization on 10 Nov 2026<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Sterile viral drug substance for vaccines and ATMPs<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Porton Advanced<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Cell and gene therapy CDMO<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">NMPA Class C license on 5 Aug 2026; 26 global INDs supported<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Commercial-stage manufacturing from China<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Nucelion Therapeutics<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">CGT CRDMO (Bharat Biotech)<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">VeGen Bio CAR-T agreement on 21 Oct 2026<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Local plasmid, vector and cell therapy production in India<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">VintaBio<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">AAV8 and vaccine CDMO, Philadelphia<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Assignment for benefit of creditors on 27 Oct 2026<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Assets offered for sale; bids due 15 Dec 2026<\/td>\n<\/tr>\n<\/table>\n<p><b>Customer and Buyer Intelligence<\/b><\/p>\n<table style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; border-collapse: collapse; width:100%; border-collapse:collapse ;\">\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Target Account Group<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Decision-Makers<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Purchase Signals<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Commercial Opportunity<\/b><\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">AAV gene therapy developers<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">CMC and technical operations heads, COOs<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">BLA submissions, pre-BLA meetings, pivotal readouts<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Commercial-scale AAV supply and process transfer<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">CAR-T and ex vivo cell therapy developers<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Supply chain and procurement leaders<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Commercial supply agreements, such as OXB with Bristol Myers Squibb<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Long-term lentiviral vector supply<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Vaccine developers and public programs<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">R&amp;D heads, government program managers<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Outbreak-response funding, GMP authorizations<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Adenoviral and MVA vector production<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Research institutes<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Translational research directors<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Public research funding, academia-industry collaboration<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Clinical-grade vector for early trials<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Pharmaceutical and biopharmaceutical sponsors<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Corporate development and M&amp;A teams<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Asset sales, facility acquisitions<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Buying or leasing installed capacity<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Media, reagent and equipment buyers<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Process development and procurement leads<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Yield-improvement partnerships<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Single-use systems, media and transfection reagents<\/td>\n<\/tr>\n<\/table>\n<p><b>How Towards Healthcare Supports Decision-Making<\/b><\/p>\n<p><b>Master Dataset.<\/b> A single, structured view of the viral vector manufacturing market by type, disease, application, end-user and region, from the 2025 base year of USD 1.82 billion to the 2035 forecast of USD 12.91 billion. It helps planners size capacity, test scenarios and decide where to build, buy or partner.<\/p>\n<p><b>Towards Healthcare Quadrant.<\/b> A positioning view of vector manufacturers and suppliers. It helps sponsors shortlist CDMOs by platform breadth and regulatory readiness, and helps providers see where rivals are consolidating.<\/p>\n<p><b>Interactive Intelligence Dashboard.<\/b> Live filtering of segments, regions and company moves, such as facility sales, license awards and earnings. It supports timing decisions on supplier outreach and investment.<\/p>\n<p><b>Quality &amp; Manufacturing Intelligence.<\/b> Coverage of GMP authorizations, CMC guidance and process trends, including suspension production, single-use systems and yield enhancers. It informs technology transfer, comparability planning and supplier audits.<\/p>\n<p><b>Customized Research.<\/b> Tailored analysis, for example AAV versus lentiviral capacity in a chosen region or an acquisition screen for available cGMP sites. It supports board-level build, buy and partner choices.<\/p>\n<table style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; border-collapse: collapse; width:100%; border-collapse:collapse ;\">\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Solution<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>What It Provides<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>How It Helps<\/b><\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Master Dataset<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Segment, regional and company data for 2025\u20132035<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Sizing, forecasting and scenario planning<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Towards Healthcare Quadrant<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Competitive positioning of providers<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Partner shortlisting and benchmarking<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Interactive Intelligence Dashboard<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Filterable, current market views<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Faster monitoring and timing decisions<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Quality &amp; Manufacturing Intelligence<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Regulatory, GMP and process insight<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Lower tech-transfer and compliance risk<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Customized Research<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Bespoke studies on a stated question<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Investment, M&amp;A and sourcing decisions<\/td>\n<\/tr>\n<\/table>\n<p><b>Why Continuously Updated Intelligence Matters<\/b><\/p>\n<p>This market moves on short and long clocks. <b>Monthly<\/b> tracking catches regulatory actions, GMP authorizations and facility sales, such as ProBioGen\u2019s November update and the VintaBio process. <b>Quarterly<\/b> cycles bring earnings and pipeline milestones, including REGENXBIO\u2019s Q3 report and Lonza\u2019s Q3 update. <b>Six-monthly<\/b> reviews align with half-year results, such as OXB\u2019s H1 report, and with contract renewals. <b>Annual<\/b> refreshes reset forecasts, guidance and capital plans, which matters most when guidance is revised mid-year.<\/p>\n<p><b>Strategic Outlook<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:4pt;\"><b>CEOs and CXOs:<\/b> With the 2026 market at USD 2.21 billion and growing at 21.64% a year, choose capacity partners by balance-sheet strength as well as technology.<\/li>\n<li style=\"margin-bottom:4pt;\"><b>Strategy and Business Development:<\/b> Screen distressed or underused cGMP assets, since the VintaBio process invites bids until 15 December 2026.<\/li>\n<li style=\"margin-bottom:4pt;\"><b>R&amp;D:<\/b> Use FDA\u2019s May 2026 CMC flexibilities to plan phase-appropriate control strategies early, particularly for AAV programs.<\/li>\n<li style=\"margin-bottom:4pt;\"><b>Procurement:<\/b> Dual-source across regions as China and India add licensed and cost-competitive capacity.<\/li>\n<li style=\"margin-bottom:4pt;\"><b>Investors:<\/b> Track order conversion, backlog and utilization, because OXB shows demand and revenue timing can diverge.<\/li>\n<li style=\"margin-bottom:4pt;\"><b>Manufacturers and Suppliers:<\/b> Pair media, enhancers and single-use systems with yield claims, as the FUJIFILM\u2013Virica collaboration does for AAV.<\/li>\n<\/ul>\n<p><b>Company Ecosystem<\/b><\/p>\n<p align=\"center\" style=\"text-align:center;\"><img decoding=\"async\" height=\"432.0px\" name=\"GNW_RichHtml_IMG\" src=\"https:\/\/ml.globenewswire.com\/Resource\/Download\/74b75073-65ad-4466-96e1-21801f677c98\/image3.png\" width=\"601.0px\" data-dpi=\"96\" data-filename=\"image3.png\" \/><\/p>\n<p align=\"center\" style=\"text-align:center;\"><b>Figure 3: Viral vector manufacturing company ecosystem<\/b><\/p>\n<p><b>Call to Action<\/b><\/p>\n<p>Decision-makers who need segment, regional and company detail behind these figures can use the full report and the options below.<\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:4pt;\"><b>Report:<\/b> <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OL-WdiTJZsGFpPFgNdeMet7arXs0WVfD5TuDVRF7MuYlfW-Vp3fvof24OSh-yiVSQk-5qcetW-9F8NooNTmnJI1lCkv384sZVWt24o14jVEGb3Xrz1GU57B2pmSKwhsSmGi1lwArUpcFzWEB5PZSVC992GhCaGmIRtv_RFFLSISyzME24XyiLlNdUufbcvWgikI9wsd9TrjyLgTwZrs2nJa7kujDR5Sbgl-7e9KRiyNidTSWxHx7wynfn5P4GEcHxxbZhndgT9S1TnMvs-D8Jw==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>https:\/\/www.towardshealthcare.com\/insights\/viral-vector-manufacturing-market-sizing<\/u><\/a><\/li>\n<li style=\"margin-bottom:4pt;\"><b>Request a sample:<\/b> <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OL-WdiTJZsGFpPFgNdeMet7arXs0WVfD5TuDVRF7MuYlfW-Vp3fvof24OSh-yiVSTVPPa2MKoXPpOJXQdgV7y9fZCKq4sjJ4Q85ILze6R9-UZDtMk375lVpofZvh7a404XMlAzUdHdv1oNwjhemzPKCoz6Da-qDggZ0u0XO9oew=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>https:\/\/www.towardshealthcare.com\/sample\/5631<\/u><\/a><\/li>\n<li style=\"margin-bottom:4pt;\"><b>Checkout:<\/b> <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OL-WdiTJZsGFpPFgNdeMet7arXs0WVfD5TuDVRF7MuYlfW-Vp3fvof24OSh-yiVSOMJKBsUJNhWzBBWG5SKeCmr8PVpCDsTMHgC7eT1qoUkvjAiEbBMvleKhIl6N8_UZY56j6mgBemb2AvY9heO56QtW3qjb4tHSMFlHacFTkzs=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>https:\/\/www.towardshealthcare.com\/checkout\/5631<\/u><\/a><\/li>\n<li style=\"margin-bottom:4pt;\"><b>Schedule a meeting:<\/b> <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OL-WdiTJZsGFpPFgNdeMet7arXs0WVfD5TuDVRF7MuYlfW-Vp3fvof24OSh-yiVSvH29FTVVoxRFi4TZu0z0-BcQwQZFR9QRVdcczkPAWsMHCgHu2HM4tWXBMG0oCZE_dVrOmszWeNhIaHQV8H2mGx-7sipMf6OSczWNU4eVzlMdMtS4aEMNgTMhmZYtLxSA\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>https:\/\/www.towardshealthcare.com\/schedule-meeting<\/u><\/a><\/li>\n<\/ul>\n<p><b>Fill out the form for relevant samples, case studies, and examples.<\/b> <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=P3xqOfNK5exeU_Mcg3zFV0kMAeSMOFewHYZc7fCs0QeTYXIukz3VG5nli0ujJ-bz6LNkSiL8PKHVnoXnsqC9rnt6KoaWpZcdhOocgjURYkEMixDrHHL8SO6EOtWaZJfl\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>sales@towardshealthcare.com<\/u><\/a><\/p>\n<p><b>Related Reports<\/b><\/p>\n<ol style=\"list-style-type:decimal;\">\n<li style=\"margin-bottom:2.5pt;\">Cell and Gene Therapy Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OL-WdiTJZsGFpPFgNdeMet7arXs0WVfD5TuDVRF7MuYlfW-Vp3fvof24OSh-yiVS2zjEHxeYCbjB8tLDV0e7Q9MtGnnu-ijH0JMb1MW_xznB-NDcE6a5RyWUklBwzt_nWUbeMhfuJpWBt6pwoPV4Q3bx9QHjBnOUNXpbeCK9y3QKPaVTv8cUCSdmIekN_wgvWWpaPrcNlO8lmIuUslpVLQe23Xhz0wHvRXiMwPfI3pI=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>https:\/\/www.towardshealthcare.com\/insights\/cell-and-gene-therapy-market<\/u><\/a><\/li>\n<li style=\"margin-bottom:2.5pt;\">Cell and Gene Therapy Manufacturing Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OL-WdiTJZsGFpPFgNdeMet7arXs0WVfD5TuDVRF7MuYlfW-Vp3fvof24OSh-yiVS2zjEHxeYCbjB8tLDV0e7Q9MtGnnu-ijH0JMb1MW_xzmP64v41AgMSp01Z78mPXXv2ayCof3vxvZT009bib8DmdycdQPyb7LgN6t_5LcFXmrZbY1uUiEsc7MQrG-Op5_7NWOjsqnLrt99r2kDxD46A_MqwwVtxPo0bf13DgkyEHgY-PoM4d7ubATeTDtRoJICV84nekCZlV1LNlzvFIZOrf5SxwwCVrBNOfNjZRpm2751YDzU_sUokDuWsgMj7Kah-WKrbJK-Pwfigd2Fzdk1KdyPhx-45jC1Q3kgAri9rm8=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>https:\/\/www.towardshealthcare.com\/insights\/cell-and-gene-therapy-manufacturing-market-experiencing-significant-growth<\/u><\/a><\/li>\n<li style=\"margin-bottom:2.5pt;\">Cell and Gene Therapy Services Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OL-WdiTJZsGFpPFgNdeMet7arXs0WVfD5TuDVRF7MuYlfW-Vp3fvof24OSh-yiVS2zjEHxeYCbjB8tLDV0e7Q0QdlbsPMZKa0x0RHPPl1GhOqEJ-7n8if2h4HOB97GTk-wljWp6xRoXggN3vmVKV8PoJ5KP7jR6PjFkQBnLDQLASIa1a_xiLG0HFeex_6fmpHEi2JJ3EM5l85s50QPFLL1ECrBKzS8RpfYlCTvbqDEDqRa-tlFqNnDXx7aAuFfTp5-liO9T0svu48xlBAht1fA==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>https:\/\/www.towardshealthcare.com\/insights\/cell-and-gene-therapy-services-market-sizing<\/u><\/a><\/li>\n<li style=\"margin-bottom:2.5pt;\">U.S. Cell and Gene Therapy CDMO Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OL-WdiTJZsGFpPFgNdeMet7arXs0WVfD5TuDVRF7MuYlfW-Vp3fvof24OSh-yiVSQcja1Bjb2JXGPB6DmrGn9O9_MF_8aQLhQhQHGxflumYIgN-kxwfPM2rQNuyuwrf4N6bg12waS7mPcfWHxNynGFnK7VXx1h-_qxYv1UO-q2GdJt8ZUCPFmvo0RGyzO8ltuC8Pqd6R9imkLokHokMcZOisJZmmphgnVkU_qtvrQ3Kvrtso9XbRXgZTRtHog8Wnxs6EnPefkDjew6_eLvE29Q==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>https:\/\/www.towardshealthcare.com\/insights\/us-cell-and-gene-therapy-cdmo-market-sizing<\/u><\/a><\/li>\n<li style=\"margin-bottom:2.5pt;\">U.S. Cell and Gene Therapy Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OL-WdiTJZsGFpPFgNdeMet7arXs0WVfD5TuDVRF7MuYlfW-Vp3fvof24OSh-yiVSQcja1Bjb2JXGPB6DmrGn9O9_MF_8aQLhQhQHGxflumYIbEZiwOk-_gV1Y8Hj17dLHY9SWdtxY-D0FJdO1FbZAUZ8vLG0OpgzJCgvFzE7m0Hup-EbMjGBSsc0IK7WFnWEsnWIwgPCiqWrN7iJJLkIJi6rFcXqf_zhkuFZPqe29EZNTyFmlKBrKUl7DZBe2G93\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>https:\/\/www.towardshealthcare.com\/insights\/us-cell-and-gene-therapy-market-sizing<\/u><\/a><\/li>\n<li style=\"margin-bottom:2.5pt;\">North America Cell and Gene Therapy Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OL-WdiTJZsGFpPFgNdeMet7arXs0WVfD5TuDVRF7MuYlfW-Vp3fvof24OSh-yiVSMEfpkjvUW2pmKtbMzZfJESd-Kj4w4AvQHTNbox1QliNiaIUdds3epzkMhwUB9tomjI0L7nkX1Mtjw5d0r7YQVWV9FY3BT1OByEE7SY34SwMBEV_6pXVL8XJjDy11itcj1aQ34uNWonW7Swi7lobO4H60mYj65XeZGYz0VgXBg0jEESnYS7PhMl2pk92U29FqIj3qR1pYTXN8ZGeA9vMQmus-yuJYFM49suYyS3B9QvI=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>https:\/\/www.towardshealthcare.com\/insights\/north-america-cell-and-gene-therapy-market-sizing<\/u><\/a><\/li>\n<li style=\"margin-bottom:2.5pt;\">Cell and Gene Therapy for Oncology Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OL-WdiTJZsGFpPFgNdeMet7arXs0WVfD5TuDVRF7MuYlfW-Vp3fvof24OSh-yiVS2zjEHxeYCbjB8tLDV0e7Q0C71oMQuVu_JkaayQfLTFOT7VRM1tJKL6fQbN8LMPUcm_ytAIB58_JYrPUol087mel_6jdxfp69CfYx4QhMhzSOk1tsXSqtMqgKyfmhSmIUP6pWDb8ufxCAbi3eZLmZ-M5JuIpEOxIZPsaiA4oqbcM3mV6BgxdI8ZJOjnX--ZKpkeDHN2ODFxRtV2X_vHtyQvRwDWOctrYd3gxJMuH8Xck=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>https:\/\/www.towardshealthcare.com\/insights\/cell-and-gene-therapy-for-oncology-market-sizing<\/u><\/a><\/li>\n<li style=\"margin-bottom:2.5pt;\">U.S. Plasmid DNA Contract Manufacturing Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OL-WdiTJZsGFpPFgNdeMet7arXs0WVfD5TuDVRF7MuYlfW-Vp3fvof24OSh-yiVSVkoyBrROn7sMms8tLOWl9Y6ANI6lQlA8BkcNJaTF4yLB0SSPqN2zkhqRCwU9J4O-ulRyCXsdllcE67mrBG0p7iNpyej4iDODsCpiFr1pvFNp0sq35sSWthBI6jcp9emggfrYEKJ8P_Iok3f4IoYhq_giIEOpVHoAwB1xrxKLjjmA0itHs0ubbH4HJe0MhZG9RWiLyzTpg7t_j47EYpeowASQHUTNta0_Y4UDNWSpP_E=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>https:\/\/www.towardshealthcare.com\/insights\/us-plasmid-dna-contract-manufacturing-market-sizing<\/u><\/a><\/li>\n<li style=\"margin-bottom:2.5pt;\">Cell Therapy Monitoring Kits Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OL-WdiTJZsGFpPFgNdeMet7arXs0WVfD5TuDVRF7MuYlfW-Vp3fvof24OSh-yiVSNUAX7aFcfv32p6jn5Q3XFXm0Tdg2fE-hJkEpP3QWCp-vlMSmytF4ZXmS30DdbbTt2rHvNWZBGmKbUz7_AsE5JoRJZlhjA1PCE7MZmcFduTcyqyqOxkSxsyOU72lQskFaakLS0at9PvxjoGpHckVJvCWNEwhHBdKDS1ZbaZdR0vHyFHv7TESeTWfFhmqkKAyAsflZaqMArszJz6pNS0Wi3w==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>https:\/\/www.towardshealthcare.com\/insights\/cell-therapy-monitoring-kits-market-sizing<\/u><\/a><\/li>\n<li style=\"margin-bottom:2.5pt;\">Cell and Gene Therapy Thawing Equipment Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OL-WdiTJZsGFpPFgNdeMet7arXs0WVfD5TuDVRF7MuYlfW-Vp3fvof24OSh-yiVS2zjEHxeYCbjB8tLDV0e7Q3rmcHaTBhEbAB_ztgLP4z9k1jUEo2RClJDtdUubs5loxcpLrucSAoTtvZRZ8LIGDemirOHukgqU6c49RzjSn5E6RIC_-Nb0li8_H-rVH2n4xxUmlM5QXFbCWztKtPWjBrlq3SznW1RrxASfj8fUJrNHzqc1m9_pnHhLwiJFbeJhKk3i6zP0PEbEKUn1CjK_DJx-v7GCnXG0I2xRH-H78v0=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>https:\/\/www.towardshealthcare.com\/insights\/cell-and-gene-therapy-thawing-equipment-market-sizing<\/u><\/a><\/li>\n<li style=\"margin-bottom:2.5pt;\">Single Use Bioprocessing Probes Sensors Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OL-WdiTJZsGFpPFgNdeMet7arXs0WVfD5TuDVRF7MuYlfW-Vp3fvof24OSh-yiVSrkA0jQhKd_6WxzXxYUGkRjMxsgrPrxufiDOCHm4ej6DGRtV6YPJhpPm-lqEF9hftRrnefSdUynnXOmDJESGaKBUJtUb8iVJ5TxxIsZWFKkjancuSehyHyDF1TF-a2iE5CAohlJs4YXSB1BMJ4n7mSpRaT_-tw-y0PIRJdK2FK2AXguHggRtfE9RXjeBmuz7fyGtyr7RkXpyusuhwYl6s0lZx4KeqIb1SUnmOOLY7EYM=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>https:\/\/www.towardshealthcare.com\/insights\/single-use-bioprocessing-probes-sensors-market-sizing<\/u><\/a><\/li>\n<li style=\"margin-bottom:2.5pt;\">U.S. Restricted Access Barrier System Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OL-WdiTJZsGFpPFgNdeMet7arXs0WVfD5TuDVRF7MuYlfW-Vp3fvof24OSh-yiVSfWI_apv3zWiBICorAzTG8NgPJJEQXruTnQNfY-CzSobZL670c8QzUNMxS0FK_SHS8YtyhlkvkKjGI2r0uL2KCN3ddZ8qCOSyMC5nqXrr_sr74CQY2HB3yeki2ZcuuTxKmzWrRWvFw5lH0L5tW4AsqFIPvCRqEEy9whL9Ved3YN_IrzCjjB5WR65GskbqyqnFrzUZVFvFUoRopWQZi-2liHPrwgYDnwkCOQg9AgTsdkU=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>https:\/\/www.towardshealthcare.com\/insights\/us-restricted-access-barrier-system-market-sizing<\/u><\/a><\/li>\n<li style=\"margin-bottom:2.5pt;\">Biopharmaceuticals Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OL-WdiTJZsGFpPFgNdeMet7arXs0WVfD5TuDVRF7MuYlfW-Vp3fvof24OSh-yiVSQqKZIv4J8NMC4AkZoeK8igpCdCpP43FYdPPV25pNpaKyOAWdF4jilIkWA3o0-sjmNYj1n_fl-b1mdqc6vBgNc7w2SPkOrlls6gIXfWWh9zcybg2ARqs-XaOP1fFsdquSc0OTsMgDgyYVCy13vVXlatM1OPexeakQREpoKXk8rEjz7doZgBBBUFjzVACpmDq3lIb0wI9Z29qp4FlEDEwWQQ==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>https:\/\/www.towardshealthcare.com\/insights\/biopharmaceuticals-market-is-rising-rapidly<\/u><\/a><\/li>\n<li style=\"margin-bottom:2.5pt;\">Biotechnology Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OL-WdiTJZsGFpPFgNdeMet7arXs0WVfD5TuDVRF7MuYlfW-Vp3fvof24OSh-yiVSAYq3caHM8bMpgizDBTDnllSJB77_jmnZTI8rKtQYZEYUx3l2disiqBgqi_0VSeOCv6Ibdh_l71aEdi_4hLYrRZOeTbgUqFJ52y6O75JmDLMu-I8E3mOMH-Xn871AHGIOM_253aZ64X67y2wRYyj3jw==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>https:\/\/www.towardshealthcare.com\/insights\/biotechnology-market<\/u><\/a><\/li>\n<li style=\"margin-bottom:2.5pt;\">Pharmaceutical Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OL-WdiTJZsGFpPFgNdeMet7arXs0WVfD5TuDVRF7MuYlfW-Vp3fvof24OSh-yiVSZZmEqNC4vRl8gfB-H0zpJB34BceHjQ14xhGFDTPOZptmJm4jN2o7i-3bMEPNcAcSCmRlgFxtodBSKIya2pMMZLhrqUv7Zbpw1pB6OGqJgDs7b5lVXVEfQVN8VRtz4WcYkFwDX_njFbaIJh_Q-XHXQZ28LohFa9b0U2agWWChWOk=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>https:\/\/www.towardshealthcare.com\/insights\/pharmaceutical-market-sizing<\/u><\/a><\/li>\n<li style=\"margin-bottom:2.5pt;\">Molecular Diagnostics Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OL-WdiTJZsGFpPFgNdeMet7arXs0WVfD5TuDVRF7MuYlfW-Vp3fvof24OSh-yiVSaqgr--s_5t891jXtGq8iZWG0fKH5_1xndXUrBDGO4aXc791jNxBQTtDZwm67YxBXEnRd0IrkDJow3baQzXCMSppF1-g0MGiFtNiygintKLsXE9p4wQsLoOd6EEerlKlxeASn61unarDfWESOf0gsMI9cXPEwXrK_2ISixQNfOjWdfHb-BgN8BVAIgSlqgKAu\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>https:\/\/www.towardshealthcare.com\/insights\/molecular-diagnostics-market-sizing<\/u><\/a><\/li>\n<li style=\"margin-bottom:2.5pt;\">Advanced Cancer Diagnostics Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OL-WdiTJZsGFpPFgNdeMet7arXs0WVfD5TuDVRF7MuYlfW-Vp3fvof24OSh-yiVSJh9LjwbAj0lfO889-U0jo37OyXbVTVmv7_sVKEChDrMVnJAGLY7XRuz9-9-pDtsZSwu4BpMpkmhwLldc3io5oimbUnjRobK7QQMWwd64SUer_GrdsdEaYi0SjaHEsN3hSON_5XF3cQ3nPNPCFKTPvraTgr7h4GJgIdy-bcVtQe_pnTizKABa1oHM5d_q_MDB2TZDd-FKoKthflAxXdc6Yw==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>https:\/\/www.towardshealthcare.com\/insights\/advanced-cancer-diagnostics-market-sizing<\/u><\/a><\/li>\n<li style=\"margin-bottom:2.5pt;\">Medical Device CMO and CDMO Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OL-WdiTJZsGFpPFgNdeMet7arXs0WVfD5TuDVRF7MuYlfW-Vp3fvof24OSh-yiVSYjKIfGg9vDz7zCyHLydfWy_fIvZ9CF-YG6ZwpvhYAWc2JlwAckPYGPE1AQiRHGv54nMzI8Aau5nbVLGHD64LWMW9H5sttZ6DZ9QUozYHSS2HLUgZOO6hQkmVhu65uuE5Wi55D1JN74eP-PW1Akae1vJvoCrQptsmHMmncCHedbMTdaMUZTqeuP_e1Tfpn836I7Y4WPrwa2o9zk-PaCLs6g==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>https:\/\/www.towardshealthcare.com\/insights\/medical-device-cmo-and-cdmo-market-sizing<\/u><\/a><\/li>\n<li style=\"margin-bottom:2.5pt;\">AI in Life Sciences Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OL-WdiTJZsGFpPFgNdeMet7arXs0WVfD5TuDVRF7MuYlfW-Vp3fvof24OSh-yiVSXwnRdNUnpS-rdBH0gP0lBQ0a5wJuckxjC_ODA0JHSi9vqLZmq2gherX7CEUEYJZy6DXYQNWOq5uguEZ89lgQf5GhHFsScOqliRPQmqnoezmutYLKXxCj2wyAXu0ZtrGnJsTxbvBC6yLGfeZOXwO2oaqeS6xeOvpsNo2UT1g_vRQ=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>https:\/\/www.towardshealthcare.com\/insights\/ai-in-life-sciences-market<\/u><\/a><\/li>\n<li style=\"margin-bottom:2.5pt;\">Bioinformatics in IVD Testing Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OL-WdiTJZsGFpPFgNdeMet7arXs0WVfD5TuDVRF7MuYlfW-Vp3fvof24OSh-yiVSyaqmthlPhqXO-5H_eO23LmI_YrJ9MIz5NFzUGrzzA3dx5RG0DOW3GqDOxH-QMKlR3U4XT3Q5j6dTL4bGiZak9koRxy4au_nmi7h_VVebP29K0nncl6Li2mg9_rOBGpZj_TyNirEqrqjST2eQa8wbpyiTgWX0snUlEnWaKkkqrI-08feov42QAjHv9ja5BXumUpuXlFyn-xQgvEDF_ilGHA==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>https:\/\/www.towardshealthcare.com\/insights\/bioinformatics-in-ivd-testing-market-sizing<\/u><\/a><\/li>\n<\/ol>\n<p><b>About Towards Healthcare<\/b><\/p>\n<p>Towards Healthcare is a healthcare-focused research and consulting firm that publishes market research reports, news and industry insights across pharmaceuticals, biotechnology, diagnostics, medical devices, healthcare IT, life sciences and cell and gene therapies. Its offerings include healthcare and cell and gene therapy intelligence platforms, an access dashboard and customized research for decision-makers. Website: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=h8FqNakEpM16OLnYnahIu3jjFIIBmvr7gNOu2YWZuuehXc8lWZWHEyQwrnN_NnXBnsV7uib58oOtmdShzYDFzF5XYcv-KXqjMCPcvRkSGMtjwaZ-7e_WW-3LNpK4it6yxzGWBAZ2QkhQ1JYSOyPnDA==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>https:\/\/www.towardshealthcare.com\/<\/u><\/a><\/p>\n<p><b>Our Partners<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:4pt;\">Precedence Research: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OL-WdiTJZsGFpPFgNdeMercyWW27QKZco71UHEOVFD9u_jvmb9ivAADUkjoa_ra3A63MXFNKizzgnCXL58hi6lTCAvkZJe7HfWWVbjjJdzMCPgFwWwqCZU9Kyad6YBBLy6ofOR8SDOlndU_krZd-TA==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>https:\/\/www.precedenceresearch.com\/<\/u><\/a><\/li>\n<li style=\"margin-bottom:4pt;\">Towards Packaging: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OL-WdiTJZsGFpPFgNdeMet7arXs0WVfD5TuDVRF7MuYfHdrdnalVOj818dBo7f7crtHsRkb8RCQsAIKz82w_OGx-weIMCzf9W51_ipvO0Nly-cumtmz5F-si4DXZjZgy\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>https:\/\/www.towardspackaging.com\/<\/u><\/a><\/li>\n<li style=\"margin-bottom:4pt;\">Towards Chemical &amp; Materials: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OL-WdiTJZsGFpPFgNdeMet7arXs0WVfD5TuDVRF7MuZjROInncWD6-uANLA52Cf0-U8drLpV2OZR0icheXNjm7sxl_S_c6QD6zkTcNTbd-6Mh4aucVwwgLP8Z0gscGrDq-8mY6w6J0EX56G0erdfjQ==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>https:\/\/www.towardschemandmaterials.com\/<\/u><\/a><\/li>\n<\/ul>\n<p><b>Connect With Us<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:4pt;\">USA: +1 804 441 9344<\/li>\n<li style=\"margin-bottom:4pt;\">APAC: +61 485 981 310 or +91 87933 22019<\/li>\n<li style=\"margin-bottom:4pt;\">Singapore: +65 3105 1271<\/li>\n<li style=\"margin-bottom:4pt;\">Europe: +44 7383 092 044<\/li>\n<li style=\"margin-bottom:4pt;\">Email: <a href=\"mailto:sales@towardshealthcare.com\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>sales@towardshealthcare.com<\/u><\/a><\/li>\n<\/ul>\n<p><b>Social Media<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:4pt;\">LinkedIn: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OL-WdiTJZsGFpPFgNdeMen6X0vHCLD0K360FUkPG0LUwbkv4EfLJZpiv0LDjSuw5hJdmzB-i0vxhA8HsAdjQ76RHQBV2cOb07CPP7oiPNG6sOLWtbcgsvu1dosNX7cXF55fRDiHYvoYtxbQN-VS6WMVPv3008AMjB-vxeS84watSxV2KPR3h0qqFcRykBKoHEkUkbDESmpiHJuasMljhLo8_O-cd0iSjoNQaZo0GH9Vw1LPA_MZApz3RPJZzdcqb\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>https:\/\/www.linkedin.com\/company\/towards-healthcare-research-and-consulting<\/u><\/a><\/li>\n<li style=\"margin-bottom:4pt;\">X: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OL-WdiTJZsGFpPFgNdeMer1DVUXvnLiKthUgI7DsuT_2lyo6cLNniihUh8swPaOcjhoIGk3NF3sQWkEIYCzLjxxda3yXLQI6d68d5vF1rQ2dkNfOYIgRT5KTY6DZF2of\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>https:\/\/x.com\/TowardsHealths<\/u><\/a><\/li>\n<li style=\"margin-bottom:4pt;\">Medium: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OL-WdiTJZsGFpPFgNdeMemHXpzTgJCbrQzDXMatN1v6APD_uClQGJ_3EuZDaulstX54Ol8P7Vi1bH3WyUtoJ2GtMWl4-Hd8zI2I0BgT1fU-YCdNltQ5sl-nUBuUI6A3_mmcNFWG2-anz_WT6i2XXUA==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>https:\/\/medium.com\/@TowardsHealthcare<\/u><\/a><\/li>\n<li style=\"margin-bottom:4pt;\">Instagram: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OL-WdiTJZsGFpPFgNdeMeqyx4m0_382aE2IVef5Oe8r0cyp65RXC21HkVDahO20AqwmmRIgFuKb2JGRU8Ps88YeW73I0A_ybcQ609Py2Zk3dZkZg9Q9t5NVaDB7HUinsIqVzlFGtbPWBHM5oPH02LC754IHMl5c9kNQLJTNaw54=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>https:\/\/www.instagram.com\/towards_healthcare<\/u><\/a><\/li>\n<li style=\"margin-bottom:4pt;\">YouTube: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OL-WdiTJZsGFpPFgNdeMeqCxGBv0w_xMYVsjG-vhBweH-8e5WcMcyStxH5kHoK1EUxpu-ZOOqxSyrfbZnYxV0hlto9ccryH4HE6abXsgLTqJUER1S2557PcvJeMPTgWZucqtGppqtgCcWEUUxJy5Cnv3MzX2LaK8cipwSjdG2c8=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>https:\/\/www.youtube.com\/@TowardsHealthcare<\/u><\/a><\/li>\n<\/ul>\n<p><img alt=\"\" src='https:\/\/ml.globenewswire.com\/media\/ZDdhOTk0NDEtNWJlMC00OThjLTgwOTQtNmEyNmU1ZGEwY2VmLTEyMTM4NDktMjAyNi0xMS0xNy1lbg==\/tiny\/Precedence-Research.png' referrerpolicy='no-referrer-when-downgrade' \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Market Climbs from USD 2.21 Billion in 2026 at a 21.64% CAGR: North America Leads, Asia-Pacific Is the Fastest-Growing Region and AAV Vectors Hold the Largest Type Share Ottawa, Nov. 17, 2026 (GLOBE NEWSWIRE) &#8212; Viral vector manufacturing, the upstream production, downstream purification and quality control of engineered, replication-deficient viruses that deliver genetic material into [&#8230;]\n","protected":false},"author":1,"featured_media":91396,"comment_status":"open","ping_status":"closed","sticky":false,"template":"Default","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-91395","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-globe-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Viral Vector Manufacturing Market to Reach USD 12.91 Billion by 2035 as Gene Therapy Developers Weigh Scale, Cost and Capacity - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/viral-vector-manufacturing-market-to-reach-usd-12-91-billion-by-2035-as-gene-therapy-developers-weigh-scale-cost-and-capacity\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Viral Vector Manufacturing Market to Reach USD 12.91 Billion by 2035 as Gene Therapy Developers Weigh Scale, Cost and Capacity\" \/>\n<meta property=\"og:description\" content=\"Market Climbs from USD 2.21 Billion in 2026 at a 21.64% CAGR: North America Leads, Asia-Pacific Is the Fastest-Growing Region and AAV Vectors Hold the\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/viral-vector-manufacturing-market-to-reach-usd-12-91-billion-by-2035-as-gene-therapy-developers-weigh-scale-cost-and-capacity\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-17T15:52:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-18T02:16:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/11\/viral-vector-manufacturing-market-to-reach-usd-12-91-billion-by-2035-as-gene-therapy-developers-weigh-scale-cost-and-capacity.png\" \/>\n\t<meta property=\"og:image:width\" content=\"2400\" \/>\n\t<meta property=\"og:image:height\" content=\"1200\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"14 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/viral-vector-manufacturing-market-to-reach-usd-12-91-billion-by-2035-as-gene-therapy-developers-weigh-scale-cost-and-capacity\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/viral-vector-manufacturing-market-to-reach-usd-12-91-billion-by-2035-as-gene-therapy-developers-weigh-scale-cost-and-capacity\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"Viral Vector Manufacturing Market to Reach USD 12.91 Billion by 2035 as Gene Therapy Developers Weigh Scale, Cost and Capacity\",\"datePublished\":\"2026-11-17T15:52:00+00:00\",\"dateModified\":\"2026-11-18T02:16:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/viral-vector-manufacturing-market-to-reach-usd-12-91-billion-by-2035-as-gene-therapy-developers-weigh-scale-cost-and-capacity\/\"},\"wordCount\":2890,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Globe Newswire\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/viral-vector-manufacturing-market-to-reach-usd-12-91-billion-by-2035-as-gene-therapy-developers-weigh-scale-cost-and-capacity\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/viral-vector-manufacturing-market-to-reach-usd-12-91-billion-by-2035-as-gene-therapy-developers-weigh-scale-cost-and-capacity\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/viral-vector-manufacturing-market-to-reach-usd-12-91-billion-by-2035-as-gene-therapy-developers-weigh-scale-cost-and-capacity\/\",\"name\":\"Viral Vector Manufacturing Market to Reach USD 12.91 Billion by 2035 as Gene Therapy Developers Weigh Scale, Cost and Capacity - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2026-11-17T15:52:00+00:00\",\"dateModified\":\"2026-11-18T02:16:28+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/viral-vector-manufacturing-market-to-reach-usd-12-91-billion-by-2035-as-gene-therapy-developers-weigh-scale-cost-and-capacity\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/viral-vector-manufacturing-market-to-reach-usd-12-91-billion-by-2035-as-gene-therapy-developers-weigh-scale-cost-and-capacity\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/viral-vector-manufacturing-market-to-reach-usd-12-91-billion-by-2035-as-gene-therapy-developers-weigh-scale-cost-and-capacity\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Viral Vector Manufacturing Market to Reach USD 12.91 Billion by 2035 as Gene Therapy Developers Weigh Scale, Cost and Capacity\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Viral Vector Manufacturing Market to Reach USD 12.91 Billion by 2035 as Gene Therapy Developers Weigh Scale, Cost and Capacity - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/viral-vector-manufacturing-market-to-reach-usd-12-91-billion-by-2035-as-gene-therapy-developers-weigh-scale-cost-and-capacity\/","og_locale":"en_US","og_type":"article","og_title":"Viral Vector Manufacturing Market to Reach USD 12.91 Billion by 2035 as Gene Therapy Developers Weigh Scale, Cost and Capacity","og_description":"Market Climbs from USD 2.21 Billion in 2026 at a 21.64% CAGR: North America Leads, Asia-Pacific Is the Fastest-Growing Region and AAV Vectors Hold the","og_url":"https:\/\/english.saigonbiz.com\/vn\/viral-vector-manufacturing-market-to-reach-usd-12-91-billion-by-2035-as-gene-therapy-developers-weigh-scale-cost-and-capacity\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2026-11-17T15:52:00+00:00","article_modified_time":"2026-11-18T02:16:28+00:00","og_image":[{"width":2400,"height":1200,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/11\/viral-vector-manufacturing-market-to-reach-usd-12-91-billion-by-2035-as-gene-therapy-developers-weigh-scale-cost-and-capacity.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"14 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/viral-vector-manufacturing-market-to-reach-usd-12-91-billion-by-2035-as-gene-therapy-developers-weigh-scale-cost-and-capacity\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/viral-vector-manufacturing-market-to-reach-usd-12-91-billion-by-2035-as-gene-therapy-developers-weigh-scale-cost-and-capacity\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"Viral Vector Manufacturing Market to Reach USD 12.91 Billion by 2035 as Gene Therapy Developers Weigh Scale, Cost and Capacity","datePublished":"2026-11-17T15:52:00+00:00","dateModified":"2026-11-18T02:16:28+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/viral-vector-manufacturing-market-to-reach-usd-12-91-billion-by-2035-as-gene-therapy-developers-weigh-scale-cost-and-capacity\/"},"wordCount":2890,"commentCount":0,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Globe Newswire"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/english.saigonbiz.com\/vn\/viral-vector-manufacturing-market-to-reach-usd-12-91-billion-by-2035-as-gene-therapy-developers-weigh-scale-cost-and-capacity\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/viral-vector-manufacturing-market-to-reach-usd-12-91-billion-by-2035-as-gene-therapy-developers-weigh-scale-cost-and-capacity\/","url":"https:\/\/english.saigonbiz.com\/vn\/viral-vector-manufacturing-market-to-reach-usd-12-91-billion-by-2035-as-gene-therapy-developers-weigh-scale-cost-and-capacity\/","name":"Viral Vector Manufacturing Market to Reach USD 12.91 Billion by 2035 as Gene Therapy Developers Weigh Scale, Cost and Capacity - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2026-11-17T15:52:00+00:00","dateModified":"2026-11-18T02:16:28+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/viral-vector-manufacturing-market-to-reach-usd-12-91-billion-by-2035-as-gene-therapy-developers-weigh-scale-cost-and-capacity\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/viral-vector-manufacturing-market-to-reach-usd-12-91-billion-by-2035-as-gene-therapy-developers-weigh-scale-cost-and-capacity\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/viral-vector-manufacturing-market-to-reach-usd-12-91-billion-by-2035-as-gene-therapy-developers-weigh-scale-cost-and-capacity\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"Viral Vector Manufacturing Market to Reach USD 12.91 Billion by 2035 as Gene Therapy Developers Weigh Scale, Cost and Capacity"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/91395","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=91395"}],"version-history":[{"count":1,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/91395\/revisions"}],"predecessor-version":[{"id":91397,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/91395\/revisions\/91397"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/91396"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=91395"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=91395"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=91395"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}